Tag: Acandis
Acandis to support ICARUS study with goal of advancing ICAD-related LVO...
Acandis has announced that it will play a supporting role in the ICARUS study, which was recently launched by University Hospital Basel (Basel, Switzerland)—under...
Lauxera invests €50 million in Acandis
Lauxera Capital Partners has invested €50 million in neurovascular medical device company Acandis—a transaction that marks the firm’s first investment out of Lauxera Growth...
HEAL coating holds potential to “alleviate some of the biggest concerns”...
This advertorial is sponsored by Acandis.
While intracranial stents are among the devices most commonly used by neurointerventionists, one challenge that hampers their utilisation in...
Recent addition to European flow diverter market performs well in multicentre...
A recent addition to Europe’s flow diversion market—the Derivo 2 embolisation device (DED2; Acandis)—has demonstrated promise in a small-scale, multicentre study, providing a safe...
APERIO hybrid thrombectomy device receives CE mark approval
Acandis GmbH announces that it has received European CE mark approval for its APERIO hybrid thrombectomy device. APERIO is intended for restoration of the...
Acandis receives European CE mark approval for its ACCERO stent
Acandis has announced that it has received European CE mark approval for its ACCERO stent, which is now available for sale in Europe. The...
Multicentre study shows Derivo embolisation device to be safe and effective...
Endovascular treatment of unruptured intracranial aneurysms with the Derivo (Acandis) embolisation device is associated with high procedural safety and adequate occlusion rates. All procedures...
Acclino stents feasible in complex bifurcation aneurysms at mid-term follow-up
A new study has found stent-assisted endovascular techniques with Acclino stents (Acandis) are a feasible treatment for complex intracranial aneurysms. Reporting in the Journal...
